Categorised under:
Interventional Radiology
>
Vascular
>
Renal denervation
Medtronic has announced that its US pivotal trial of renal denervation for treatment resistant hypertension SYMPLICITY HTN-3 has failed to reach its primary efficacy endpoint.
The promising results were announced after a randomised trial on Medtronic's Symplicity Catheter System.
Renal sympathetic denervation (RDN) has been a dominant theme in the endovascular community during 2012. With this excitement, the past year has seen the introduction of several new devices and the release of longer term trial data.
Hypertension is a global problem affecting approximately 1 billion people (2000 estimate) and this number is set to increase by a further 500 million by 2025...
User warkworth16 has asked for help in sourcing the equipment to perform renal sympathetic nerve ablation therapy to treat his wife who suffers from severe refractory hypertension.
Did you know you can Register for FREE with this website?
Registration gives you full access to all of the features of WhichMedicalDevice. Find out more ...
WhichMedicalDevice is a FREE resource created by clinicians for clinicians.
Registration is free and gives you unlimited access to all of the content and features of this website.
Find out more...Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...
Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.
We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.